Lilly may launch tirzepatide to treat obesity later this year (NYSE:LLY)

Lilly Biotechnology Center in San Diego, California, USA.

Photo JHVE

Eli Lilly (NYSE:LLY) believes its diabetes drug Mounjaro (tirzepatide) will have additional indications for the treatment of obesity as early as the end of the year, according to CFO Anat Ashkenazi.

Speaking at the JP Morgan Medical Conference, Ashkenazi added

Source by [author_name]


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button